Seminars in Oncology
Volume 30, Issue 3 , Pages 361-368, June 2003

Evidence-based follow-up of lung cancer patients

  • Thomas J. Smith

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine and Massey Cancer Center; Williamson Institute of Health Economics, Department of Health Administration, Virginia Commonwealth University, Richmond, VA, USA
    • *Address reprint requests to Thomas J. Smith, MD, FACP, Division of Hematology/Oncology and Palliative Care, MCV PO Box 980230, 1101 E Marshall St, Richmond, VA 23298-0230 USA

Abstract 

Evidence-based follow-up care of the lung cancer patient is straightforward with periodic histories and physical examinations recommended to detect recurrence. Yearly chest radiographs to detect second primaries “may be reasonable” in small and non-small cell lung cancer patients. The routine use of computed axial tomography (CAT) scans, bone scans, brain imaging, and serum tumor markers is not recommended in lung cancer patients. Many patients receive more extensive and expensive follow-up after treatment, despite the lack of curative options for recurrent lung cancer or evidence that earlier treatment of recurrence leads to better medical outcomes. The reasons for this are not known at present but could involve patient or physician preference, with no disincentives for extra testing. Adherence to breast cancer follow-up clinical practice guidelines at one cancer center reduced cost by one third with no change in health outcomes, but no studies have been performed in lung cancer.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(03)00148-9

Seminars in Oncology
Volume 30, Issue 3 , Pages 361-368, June 2003